
Minerva Neurosciences Inc
NERVNASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$4.98
Day High
$5.01
Day Low
$4.85
Prev. Close
$5.00
VolumeShares traded today.
56.84K
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$228.75M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-0.17
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$12.46
52W LowLowest price over the past 52 weeks.
$1.55
50D MAAverage closing price over the last 50 trading days.
$5.95
200D MAAverage closing price over the last 200 trading days.
$4.51
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
-7.4%1M
-23.2%6M
+30.2%YTD
+25.3%1Y
+214.7%About
MIN-117 is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD. In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.
www.minervaneurosciences.com/Company Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade NERV
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.